Exosomes - Pipeline Insight, 2020

Publisher Name :
Date: 24-Sep-2020
No. of pages: 110
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Exosomes - Pipeline Insight, 2020" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Exosomes Understanding

Exosomes: Overview

Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)—an intermediate endocytic compartment—with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB—a type of intraluminal vesicles (ILV's)—buds inward into the endosomal lumen. Exosomes, produced in endosomal compartment of most eukaryotic cells, are released in the form of ILV's in instances where the MVB fuses with the cell surface (the plasma membrane). The exosomes and other extracellular vesicles (EV's) are present in tissues of the multicellular organisms, including biological fluids, such as blood, urine, and cerebrospinal fluid. They can also be released in vitro by the cultured cells into their growth medium.

Characteristics of Exosomes and Function

Exosomes are basically formed by the cellular endocytic pathway, which consists of three different stages:

- The plasma membrane invagination from the endocytic vesicles.

- The second stage is the inward building of endosomal membrane which gives rise to multivesicular bodies (MVB's).

- The third and the last stage is when the MVB's fuse with the plasma membrane and releases the vesicular contents, which in turn forms the exosomes.

The membrane proteins, which undergo the endosomal pathway, exhibit the same stages. Different types of lipidic molecules are known for their involvement in the exosome formation and release like phosphatidic acid and ceramides.

Composition

Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. One can use all of these proteins as positive markers.

Biological functions of Exosomes

Exosomes are nano-sized EVs that have impressive physiological properties and emerge through the inward budding of the late endosomal membrane called multivesicular bodies (MVBs). As MVBs are fused with the plasma membrane, exosomes are released into the extracellular environment. They can either be taken up by target cells residing in the microenvironment or transported by biological fluids to distant sites. Exosomes have a small diameter range of 40-100 nm and a density of 1.13-1.19 g/ml in sucrose solution. They can be sedimented at 100,000 g by centrifugation. Also, exosome membranes are enriched with proteins from cholesterol, sphingomyelin, ceramide and lipid raft.

Exosomes Emerging Drugs Chapters

This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs

- Neural exosomes (AB126): ArunA Biomedical

ArunA Biomedical's proprietary neural exosomes cross the blood-brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the therapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system's self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.

- ExoPr0: ReNeuron

Company's CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resource to the application of ExoPr0 as a vector for delivering drugs.

- exoIL-12: Codiak Biosciences

exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak's proprietary scaffold protein, PTGRFN. Developed via Codiak's proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak's preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.

Further product details are provided in the report……..

Exosomes: Therapeutic Assessment

This segment of the report provides insights about the different Exosomes based drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Exosomes

There are approx. 50+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the early stages, i.e. phase I include United Therapeutics Corporation.

- Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

- Late-stage products (Phase II and Phase II/III)

- Mid-stage products (Phase II and Phase II/III)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Intramuscular

- Intranasal

- Parenteral

- Intravenous

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Small molecules

- Vaccines

- Polymers

- Peptides

- Enzymes

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches to treat/improve Exosomes.

- Anjarium's Hybridosome platform, coupled with the targeting technology and proprietary manufacturing methods, is a promising technology to overcome the delivery hurdles today's most potent RNA therapeutic candidates face.

- Therapeutic Benefits: Exosomes are directly internalized by recipient cells, which prevent a multiplicity of potential concerns associated with the administration of living cells, and exosomes have therapeutic benefits, at least equivalent to their cellular source.

Exosomes Report Insights

- Exosomes Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Exosomes Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Exosomes drugs?

- How many Exosomes drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Exosomes?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Exosomes and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Direct Biologics

- Codiak BioSciences

- ExoCyte Therapeutics

- Avalon GloboCare

- United Therapeutics Corporation

- Capricor Therapeutics

- Avalon GloboCare

- Azymus Therapeutics

- Versatope Therapeutics

- Lamellar Biomedical

- Celltrion

Key Products

- LAMELLASOME IPF-NA

- exoSTING

- ET-08

- AVA 201

- Unexisome

- CAP 2003

- exoIL 12

- AVA 203

- AZ 001

- VT 105

Exosomes - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Exosomes: Overview
* Characteristics of Exosomes and Function
o Formation
* Extracellular vesicles
* Composition
* Exosome Release
* Exosome Uptake
* Biological functions of Exosomes
* Exosomes as a therapeutic target
* Isolation and Characterisation of Exosomes
* Therapeutic Preparation of Exosomes
* Biomedical application
o Exosomes in CNS Disease
o Exosomes in Oncology
o Exosomes in Other Diseases
* Advantages and disadvantages
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Exosomes - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Exosomes companies' collaborations, Licensing, Acquisition -Deal Value Trends
Exosomes Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase I/II)
* Comparative Analysis
MPCs-derived exosomes: Cellular Biomedicine Group Ltd.
* Product Description
* Research and Development
* Product Development Activities
AGLE 102: Aegle Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
* Comparative Analysis
exoSTING: Codiak BioSciences
* Product Description
* Research and Development
* Product Development Activities
AVA 201: Avalon GloboCare
* Product Description
* Research and Development
* Product Development Activities
UNEX 42: United Therapeutics Corporation
* Product Description
* Research and Development
* Product Development Activities
CAP 2003: Capricor Therapeutics
* Product Description
* Research and Development
* Product Development Activities
AB 126: ArunA Biomedical
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix

List of Tables

Table 1 Total Products for Exosomes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Exosomes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Lenvatinib Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 130
    According to this study, over the next five years the Lenvatinib market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Lenvatinib business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Lenvatinib market by product type, application, key......
  • Global Levoxyl Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Levoxyl market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Levoxyl business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Levoxyl market by product type, application, key manufact......
  • Global Emergency Contraceptive Pills Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Emergency Contraceptive Pills market will register a 3.2%% CAGR in terms of revenue, the global market size will reach $ 543.7 million by 2025, from $ 478.7 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Emergency Contraceptive Pills business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Emerge......
  • Global Trichomonas Rapid Testing Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Trichomonas Rapid Testing market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Trichomonas Rapid Testing business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Trichomonas Rapid Tes......
  • Global Topical Excipients Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 132
    According to this study, over the next five years the Topical Excipients market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Excipients business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Topical Excipients market by produc......
  • Global Topical Antibiotic Pharmaceuticals Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Topical Antibiotic Pharmaceuticals market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Antibiotic Pharmaceuticals business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Top......
  • Global Tissue-Replacement Products Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 136
    According to this study, over the next five years the Tissue-Replacement Products market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue-Replacement Products business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue-Replacemen......
  • Global Tissue Glue and Bio-adhesive Sealants Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 139
    According to this study, over the next five years the Tissue Glue and Bio-adhesive Sealants market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Glue and Bio-adhesive Sealants business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities ......
  • Global Tissue Culture Reagents Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Tissue Culture Reagents market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Culture Reagents business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue Culture Reagents m......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs